<DOC>
	<DOCNO>NCT00601523</DOCNO>
	<brief_summary>The general aim study obtain long-term safety tolerability data pramipexole ER , daily dose 0.375mg 4.5mg daily ( q.d ) , patient previously complete pramipexole double-blind study early PD ( 248.524 ( NCT00479401 ) 248.636 ( NCT00558025 ) trial ) .</brief_summary>
	<brief_title>Long-term Safety Study Open-label Pramipexole Extended Release ( ER ) Patients With Early Parkinson´s Disease ( PD ) .</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : 1 . Completion doubleblind trial 248.524 248.636 2 . Male female patient early idiopathic Parkinson´s disease ( PD ) , Modified Hoehn Yahr stage I III . 3 . Patient willing able comply schedule visit , treatment plan , laboratory test study procedure . 4 . Signed informed consent obtain study procedure carry ( accordance International Conference Harmonisation ( ICH ) Good Clinical Practice ( GCP ) guideline local legislation ) . Exclusion criterion : 1 . Patients prematurely withdraw doubleblind trial 248.524 248.636 . 2 . Atypical parkinsonian syndrome due drug , metabolic disorder , encephalitis degenerative disease . 3 . Any psychiatric disorder accord Diagnostic Statistical Manual Mental Disorders , fourth edition ( DSMIV ) criterion could prevent compliance completion study and/or put patient risk he/she take part study.4.History psychosis , except history drug induce hallucination . 5 . Clinically significant electrocardiogram ( ECG ) abnormalities baseline . 6.Clinically significant hypotension 7.Malignant melanoma history previously treat malignant melanoma . 8.Any clinically significant disease , could put patient risk could prevent compliance completion study . 9 . Pregnancy breastfeed . 10 . Sexually active female childbearing potential use medically approve method birth control least one month prior baseline throughout study.11 Serum level aspartate aminotransferase ( AST ) ( SGOT ) , alanine aminotransferase ( ALT ) ( SGPT ) , alkaline phosphatase bilirubin &gt; 2 upper limit normal ( ULN ) baseline 12 . Patients creatinine clearance &lt; 50 mL/min ( estimate Cockcroft Gault formula ) . 13 . Motor complication levodopa therapy ( e.g . onoff phenomenon , dyskinesia ) baseline . 14 . Any medication ( include intramuscular formulation ) central dopaminergic antagonist activity within 4 week prior baseline visit . 15.Any follow drug within 4 week prior baseline : methylphenidate , cinnarizine , amphetamine . 16 . Flunarizine within 3 month prior baseline . 17 . Known hypersensitivity pramipexole excipients . 18 . Drug abuse ( include alcohol ) , accord investigator´s judgement , within 2 year prior baseline . 19 . Participation investigational drug study trials 248.524 248.636 use investigational drug within one month five time halflife investigational drug prior baseline .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>